Posted from: Monday, October 05, 2015 - 05:02 PM - Present

Ximino Approved for Certain Patients with Acne

August 24, 2015 – The U.S. Food and Drug Administration (FDA) approved Ximino (minocycline HCl) extended release capsules for inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 12 years of age and older. Ximino, manufactured by Sun Pharmaceutical, is a tretracycline antibiotic that will be available in 45mg, 90mg, and 135mg extended-release capsules. Recommended dosage is approximately 1mg/kg once daily for 12 weeks. Sun Pharmaceutical plans on launching Ximino during the last quarter of 2015.

Adverse reactions or quality problems experienced with the use of a recalled product may be reported to the FDA’s MedWatch Adverse Event Reporting Program either online, by regular mail or by fax.

Actual drug patent expiration dates and a availability of new medications are subject to change due to patent litigation, settlement agreements, additional patents, exclusivities, and final FDA approval.  Distribution and availability of new medications at pharmacies may not occur immediately following FDA approval.  Patients are advised to speak with their healthcare professional or pharmacist regarding appropriateness as well as actual availability. All trademarks are the property of their respective owners.

*This is provided for information only.  The reference to any medication above does not mean the medication is covered by your plan.

 

Last Updated Monday, December 11, 2017 - 02:21 AM.